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Background: Successful treatment of anaphylaxis in the community relies on early and correct use of epinephrine
autoinjectors. Community pharmacists supply these devices and have a crucial role teaching patients how to use
them. Supply of epinephrine autoinjectors in Australia increased 70-fold in the past decade. New EpiPen and Anapen
autoinjectors were launched in Australia in 2011 and 2012, with the potential to cause confusion. However there is no
information about how pharmacists demonstrate epinephrine autoinjectors to patients. Therefore the aim of this study
was to assess real-world community pharmacist demonstrations of EpiPen and Anapen. We also sought to identify
consultation-based predictors of accurate demonstration.
Methods: Demonstration accuracy was assessed in simulated patient visits to 300 randomly selected pharmacies.
Pharmacists were asked by the simulated patient how to use original EpiPen, new-look EpiPen or Anapen, and assessed
against the relevant Australasian Society of Clinical Immunology and Allergy (ASCIA) Action Plan for Anaphylaxis. Other
anaphylaxis advice provided by the pharmacist was also recorded. Accuracy was analysed descriptively. Binary logistic
regression was used to identify predictors of accurate demonstration.
Results: All 300 pharmacies were visited. Of 250 pharmacist demonstrations, 46 (18.4%) accurately demonstrated all
four steps on ASCIA Action Plan. Failure to state ‘do not touch the needle’ (74.8%) or ‘massage injection site’ (68.8%)
reduced accuracy. However 163 (65.2%) accurately demonstrated the three steps required to inject epinephrine
(no difference by device, p = 0.15). Associations with accurate demonstration were: checking if the patient had an
anaphylaxis action plan (odds ratio, OR = 16.1; 95% CI: 3.86-67.3); stating to call an ambulance after use (OR = 4.0; 95%
CI: 1.44-11.1); or explaining side effects of epinephrine (OR = 4.5; 95% CI: 1.48-13.4).
Conclusions: It is critical that anaphylaxis patients know how to use their prescribed epinephrine autoinjector correctly.
Pharmacists have acceptable rates of EpiPen and Anapen demonstration accuracy, although more is needed to
improve this. Those who pay attention to the need for action plans, emergency care after epinephrine use, and
informing patients about the side effects of epinephrine may have better knowledge about anaphylaxis, and in turn
significantly improve demonstration accuracy.
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Anaphylaxis is a severe, progressive, allergic reaction
that is rapid in onset and can cause death [1]. Anaphylaxis
in the community is common, and increasing as severe
allergies to food and insect venom rise [2-5]. Early treatment
with epinephrine is essential to reduce mortality [3,6-10].
However, in the community setting, this can represent
a potentially deadly challenge for patients without
immediate access to a healthcare professional. Epinephrine
autoinjectors are frequently prescribed to anaphylaxis
patients to enable rapid first aid before medical attention
is sought [8,9,11]. Although not universally available, these
devices exist in Australia, Canada, the United States,
Europe, the United Kingdom, Asia, Africa, South America,
and the Middle East [12].
In Australia, epinephrine autoinjectors (EpiPen and
Anapen devices) may be obtained with or without a
physician’s prescription [13,14]. Devices supplied on
prescription are subsidised through the Medicare Australia
Pharmaceutical Benefits Scheme (PBS). Supply is restricted
to patients who have experienced anaphylaxis, or who have
been declared high-risk for anaphylaxis, by a specialist aller-
gist, pediatrician, emergency room physician or respiratory
physician. Before the listing of Anapen in 2010, EpiPen was
the sole device available in Australia. A new-look EpiPen
became available in 2011, and for a period all three devices
were sold (original EpiPen, new-look EpiPen, Anapen). In
2003, PBS funding for epinephrine autoinjectors totalled
AU$188,000. In 2013, this had risen to nearly AU$13
million; almost a 70-fold increase [15]. All of these devices
were prescribed by physicians, and supplied to patients by
pharmacists in community pharmacies.
It is well established that teaching patients how and when
to use their autoinjector is central to sound anaphylaxis
preparedness and management [3,8,10,11,16]. Alongside an
understanding of the importance of timely injection is
the need for correct injection technique. Erroneous
injection, typically to a digit or hand, results in a lost dose
of epinephrine for the patient (a potentially fatal error), as
well as injury to the caregiver [17,18]. Vigilance in training
and reminding patients on correct the use of epinephrine is
crucial to prevent anaphylaxis deaths. Physicians provide
this training during consultations, although when assessed
they have been shown to be poor demonstrators of autoin-
jectors [19-22]. Patients have been shown to be inconsistent
with recall, and need to be regularly reminded how to use
their device [20,22-27].
Pharmacists are an important link for interdisciplinary
care between physician and patient. As pharmacists see
patients every time an epinephrine autoinjector is supplied,
they have a unique role in teaching them how to use their
device. Yet there is little research evaluating this. Studies in
this area are limited to evaluation of EpiPen demonstration
rates and open assessment of EpiPen demonstration steps[19,28]. There is no blinded research assessing real-world
epinephrine autoinjector technique in pharmacists,
patients or other health professionals. Although Anapen is
available in the United Kingdom, Europe and Australia,
there is no research evaluating its demonstration by
pharmacists, and few evaluations in other groups [23,27].
Our primary aim was to investigate how accurately
Australian community pharmacists demonstrated epi-
nephrine autoinjectors to patients under real-world
conditions. Pharmacists are routinely exposed to these
devices, therefore we hypothesized they would have high
rates of demonstration accuracy. Secondly, we considered
that changes in epinephrine autoinjector availability in
Australia (in 2010–2011) would cause confusion, and
hypothesized that demonstration accuracy would vary
between devices. In this instance we expected pharmacists
would be most familiar with original EpiPen (as for more
than 10 years this was the only device available in
Australia); but not familiar with Anapen (a new device
with different administration technique). Since new-look
EpiPen was replacing original EpiPen (and they have
similar technique), we expected accuracy to be similar
between these devices, and higher in both compared
to Anapen. Finally, we sought to identify predictors of
accurate demonstration based on the features of the
consultation with the pharmacist.
Methods
We conducted a randomised, cross-sectional, simulated
patient study of community pharmacist practice in
Perth, Australia, from April-May 2012. Approval for the
study was received from The University of Western
Australia Human Research Ethics Committee in March
2012 (Approval number RA/4/1/5440). A random sample
of 300 pharmacies (located within a 20 km radius of the
Perth Central Business District, and listed on the Pharmacy
Registration Board of Western Australia Premises Register
[13]) was selected using a random numbers generator [29].
Pharmacies were randomly assigned to original EpiPen,
new-look EpiPen or Anapen groups. Where the researcher
recognised the pharmacist or any other staff member on
duty, the visit was abandoned and the pharmacy excluded.
Devices were allocated to researchers randomly.
Original EpiPen was allocated to a female Master of
Pharmacy student, aged 20–25 years. New-look EpiPen
was allocated to a male Master of Pharmacy student, aged
20–25 years. Anapen was allocated to an experienced
simulated patient actor (female, aged 40–45 years). At
each visit the researcher enacted a scenario of a patient
who had experienced their first episode of anaphylaxis
‘one week ago’. Researchers carried two of the same
unmarked, epinephrine autoinjector devices. All devices
were new and within their expiry date, and replenished as
required to ensure they appeared new for each pharmacy
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pharmacist on duty, before showing their device and
asking how to use it. Immediately after the visit (away
from the premises) the researcher completed a data
collection tool and subsequently entered data into a data-
base [Microsoft Excel, Microsoft Corporation, Redmond,
United States of America].
Prior to the study, we assessed the usability of the
scenario during a full-day training and evaluation session.
Researchers practised the role of the simulated patient,
and learnt a ‘script’ so that all opening scenario statements
and responses to pharmacist questions were the same for
each researcher. Questions that might be asked by the
pharmacist were anticipated and responses practised
during the training session. If a pharmacist asked any
question beyond those anticipated and for which
responses had been pre-prepared, researchers answered
either “I can’t remember” or “I don’t know”. EpiPen and
Anapen trainers were used to teach researchers correct
device demonstration, and device technique assessed to
ensure accuracy.
The data collection tool captured demographic variables
(broadly: pharmacy environment, pharmacist age group and
gender), and self-injectable epinephrine variables (broadly:
materials used for demonstration, use of references,
steps used in demonstration, errors or omissions in
demonstration and other advice provided). Prior to
use, the tool was evaluated for face validity in a group
of ten pharmacists and evaluated for usability in a
round-table discussion during the training session.
The scenario and data collection tool were piloted in
a random sample of 9 pharmacies (3 per device). The
scenario remained unchanged. Minor changes to the
tool were made prior to the main study. Pharmacies
visited in the pilot were not included in the final analysis.
During the study, an independent auditor cross-checked
a random sample of 30 completed tools against data
entered in the database. The proportion of records in
disagreement was 0.27%. Data in disagreement were cor-
rected in the database prior to analysis.
We did not seek ethics approval to conduct con-
cealed video or audio recordings in this study becauseTable 1 Steps for accurate demonstration of epinephrine auto
Original EpiPen New-look Ep
Step 1: Remove
safety caps
Form a fist around EpiPen and
remove gray safety cap




Place black end against outer mid





Push down hard until a click is heard
or felt and hold in place for 10 seconds
Push down ha
or felt and ho
Step 4: Remove
and massage site
Remove EpiPen and do not touch needle.
Massage injection site for 10 seconds
Remove EpiPe
for 10 second
*Steps as listed on the relevant ASCIA Action Plan for Anaphylaxis at the time of thidemonstration is a moving visual and tactile task that is
difficult to record covertly. In addition, audio recordings
would not have been able to identify important features of
the demonstration such as order of removal of safety caps,
positioning of thumb, selection of location for injection
and most importantly, which end of the device was shown
as the needle end.
Accurate demonstration of epinephrine autoinjectors
was defined as one that fulfilled all steps listed on the
relevant Australasian Society of Clinical Immunology
and Allergy (ASCIA) Action Plan for Anaphylaxis [30];
(Table 1). Errors and omissions in demonstration were
recorded, along with materials used for demonstration
and any additional advice provided by the pharmacist.
Analysis
All analyses were performed using SPSS v21 [IBM,
New York, United States of America], and statistical
tests reported as two-sided p-values at the 5% level of
significance. Data are presented as frequencies, with
associations tested using the Pearson chi-squared test
or Fisher’s exact test. Compounding pharmacies and
private hospital dispensaries were excluded from analysis
as they may not routinely supply epinephrine autoinjectors
or be directly accessible by patients.
Binary logistic regression was performed to identify
consultation-specific predictors of accurate EpiPen and
Anapen demonstration. Potential predictors in the model
were device type, age, gender, use of references, and general
anaphylaxis and device-specific information provided by
the pharmacist. Recognising that consultations with
pharmacists may vary from brief to extended interactions
(and thus to assess the impact of predictor variables
independently and collectively), we conducted both
single variable and multi variable (adjusted) logistic
regression analyses. Odds ratios and 95% confidence intervals
for each predictor were obtained.
Results
We visited all 300 pharmacies randomised to the study.
We excluded 34 pharmacies (pilot study n = 9, known
pharmacist n = 9, private hospital dispensary n = 8, premisesinjectors*
iPen Anapen
und EpiPen and pull
release
1. Pull off black needle shield
2. Pull off gray safety cap from red button
end against outer mid thigh
ut clothing)
Place needle end firmly against outer
mid-thigh (with or without clothing)
rd until a click is heard
ld in place for 10 seconds
Press red button so it clicks and hold
in place for 10 seconds.
n. Massage injection site
s.
Remove Anapen and do not touch needle.
Massage injection site for 10 seconds.
s research [30].
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on premises n = 1). Hence, 266 (89%) of the visits were
included in the final analysis. Despite randomisation, there
was significant variability in the type/location of pharmacies
visited and estimated pharmacist age, between EpiPen and
Anapen groups. There was no difference in pharmacist
gender between groups (slightly more were female: n = 155;
58.3%, p = 0.94); Table 2.
Demonstration accuracy
Of the 266 pharmacists asked to demonstrate a device, 16
(6%) refused (4 for original EpiPen, 5 for new-look EpiPen
and 7 for Anapen). Overall, 46/250 (18.4%) pharmacists
who agreed to demonstrate the device accurately demon-
strated all four steps of the relevant ASCIA Action Plan (sig-
nificantly fewer for original EpiPen than new-look EpiPen
or Anapen, p = 0.04, see Table 2). Overall, 222 (88.8%) phar-
macists correctly demonstrated removal of safety caps (step
1), and 240 (96.0%) correctly demonstrated placement of
the device against the mid-anterolateral thigh (step 2).
Furthermore, 182 (72.8%) pharmacists correctly demon-
strated how to inject (step 3). However, only 52 (20.8%)
pharmacists correctly advised what to do with the device
after injection (step 4). Considering the first 3 steps as those
integral to receiving a dose of epinephrine, a total of 163/
250 (65.2%) pharmacists completed these correctly (Table 3),
with no difference between device groups (p = 0.15).
There was no difference in demonstration accuracy
based on pharmacy type (p = 0.29 for comparison ofTable 2 Pharmacy and pharmacist characteristics (count and
Characteristic Original EpiPen New-look Epi
n = 87 (32.7) n = 92 (34.6)
Pharmacies
Pharmacy type
Independent 43 (49.5) 47 (51.1)
Chain 31 (35.6) 40 (43.5)
Discount/warehouse 13 (14.9) 5 (5.4)
Pharmacy location
Street 52 (59.8) 49 (53.3)
Medical centre 8 (9.2) 6 (6.5)
Shopping centre 27 (31) 37 (40.2)
Pharmacists
Gender
Male 35 (40.2) 39 (42.4)
Estimated age (years)
20-30 35 (40.2) 46 (50)
31-40 32 (36.8) 20 (21.7)
41-50 11 (12.6) 18 (19.6)
51+ 9 (10.3) 8 (8.7)
*Pearson chi-squared p-value for comparison of demographic variable categories ac4-step accuracy, and p = 0.42 for comparison of 3-step
accuracy; across independent, chain and discount
pharmacies). Similarly, accuracy did not differ by
pharmacy location (p = 0.89 for comparison of 4-step
accuracy, and p = 0.86 for comparison of 3-step accur-
acy; across street, shopping centre, and medical centre
locations).
Demonstration errors
The most frequent errors in demonstration were failure
to state ‘do not touch the needle’ after injecting original
EpiPen or Anapen (n = 122/163, 74.8%), or ‘massage
injection site after use’ (n = 172/250, 68.8%); Figure 1.
Other common errors included failure to state ‘hold in
place for 10 seconds’ after injection (n = 70/250, 28%); or
‘push down hard/press the red button until a click is
heard’ (n = 53/250, 21.2%). Incorrect positioning of the
thumb over either end of the EpiPen was observed in
20/170 (11.8%) pharmacists.
Demonstration materials and anaphylaxis advice
Significantly more pharmacists in the Anapen group
demonstrated using the researcher’s live device (82.5%
compared to 59.4% for EpiPen, p < 0.001, see Table 4).
Few pharmacists used their own trainer devices (3.6%
for original EpiPen, 24.1% for new-look EpiPen and 6.3%
for Anapen) with the most use occurring in the
new-look EpiPen group, p < 0.001. Over half (58.4%) of
the pharmacists consulted reference materials including%)
Pen Anapen Total P value*
n = 87 (32.7) n = 266 (100)
0.04
36 (41.4) 126 (47.4)
46 (52.9) 117 (44)
5 (5.7) 23 (8.6)
0.01
30 (34.5) 131 (49.2)
13 (14.9) 27 (10.2)
44 (50.6) 108 (39.9)
0.94
37 (42.5) 111 (41.7)
0.03
25 (28.7) 106 (39.8)
34 (39.1) 86 (32.3)
22 (25.3) 51 (19.2)
6 (6.9) 23 (8.6)
ross groups.
Table 3 Accuracy of self-injectable epinephrine device demonstration (count and %)
Demonstration
performed
Original EpiPen New-look EpiPen Anapen Total P value*
(n = 83) (n = 87) (n = 80) (n = 250)
Step 1 69 (83.1) 76 (87.4) 75 (93.8)a 222 (86.8) 0.11
78 (97.5)b
Step 2 80 (96.4) 84 (96.6) 76 (95) 240 (96.0) 0.86
Step 3 62 (74.7) 59 (67.8) 61 (76.3) 182 (72.8) 0.42
Step 4 8 (9.6) 26 (29.9) 18 (22.5) 52 (20.8) 0.005
Steps 1-3 50 (60.2) 54 (62.1) 59 (73.8) 163 (65.2) 0.15
Steps 1-4 8 (9.6) 21 (24.1) 17 (21.3) 46 (18.4) 0.04
*Pearson chi-squared p-value for comparison of demonstration accuracy across groups. Step 1: Remove safety caps; Step 2: Place against mid-anterolateral thigh;
Step 3: Push down hard/press red button to inject and hold for 10 seconds; Step 4: Remove device, avoid needle, massage site. aRemove black needle shield.
bRemove gray safety cap from red button (Anapen only).
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demonstrate, with 80-90% referring the researcher to the
instructions on their device during demonstration. Of
those consulting reference materials, 25/146 (17.1%)
proceeded to accurately demonstrate the device (1 for
original EpiPen, 10 for new-look EpiPen and 14 for
Anapen; p = 0.002 for group comparison). However,
96/146 (65.8%) correctly demonstrated steps 1–3 (26 for
original EpiPen, 33 for new-look EpiPen and 37 for
Anapen; p = 0.04 for group comparison).
Most pharmacists explained the signs of anaphylaxis
(65.4%, see Table 5), asked if the researcher was aware of
the precipitating allergen (66.9%), told the researcher to
call an ambulance after using epinephrine (59.8%), and
examined the expiry date of the device (49.6%). Pharmacists
rarely checked if the patient had an anaphylaxis
action plan (5.6%), or explained the side effects of
epinephrine (7.9%). Compared to those demonstrating the
EpiPens, significantly fewer pharmacists demonstrating
Anapen explained the signs of anaphylaxis (p < 0.001),
asked about the precipitating allergen (p = 0.001); orFigure 1 Errors and omissions in epinephrine autoinjector device demchecked if the researcher had an anaphylaxis action plan
(p = 0.02); Table 4.
Predictors of accurate demonstration
Odds ratios (OR) from the logistic regression models
for predictors of accurate device demonstration are
presented in Table 6. There were three significant
predictors identified in both the simple and multiple
regression analyses. Accurate demonstration (as part
of the consultation) was more likely to occur when
pharmacists: (i) asked about an anaphylaxis action plan
(adjusted OR 16.1, 95% CI: 3.86-67.3); (ii) advised the
researcher to call an ambulance after epinephrine use
(adjusted OR 4.00, 95% CI: 1.44-11.1); or (iii) explained the
side effects of epinephrine (adjusted OR 4.45 95% CI:
1.48-13.4). Additionally, in brief consultations where
pharmacists may have provided just one piece of additional
advice, simply explaining the signs of anaphylaxis or the
conditions for device storage doubled the likelihood of
accurate demonstration (OR 2.14 and 2.16 respectively).
Age and gender did not impact on whether the pharmacistonstration by pharmacists.
Table 4 Materials used by pharmacists in self- injectable epinephrine device demonstration (count and %)
Original EpiPen New-look EpiPen Anapen Total P value*
(n = 83) (n = 87) (n = 80) (n = 250)
Researcher’s live device 50 (60.2) 51 (58.6) 66 (82.5) 167 (66.8) <0.001
Pharmacist’s trainer device 3 (3.6) 21 (24.1) 5 (6.3) 29 (11.6) <0.001
Consulted reference materials before demonstration 44 (53.0) 56 (64.4) 46 (57.5) 146 (58.4) 0.25
Showed instructions on researcher’s device 75 (90.4) 81 (93.1) 64 (80.0) 220 (88.0) 0.02
*Pearson chi-squared p-value for comparison of materials used for demonstration across groups.
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in accuracy between new-look EpiPen and Anapen groups.
However, those demonstrating the original EpiPen were
4.8 times less likely to do so accurately compared with the
Anapen group (95% CI: 1.59-14.3; p = 0.006). Finally, the
use of reference materials prior to demonstration did not
impact on the likelihood of accurate demonstration.
Discussion
Self-injectable epinephrine is the cornerstone of emer-
gency management for anaphylaxis occurring in the
community, and accurate administration technique is
critical for successful use during acute events. This is the
largest study of epinephrine autoinjector demonstration
by community pharmacists, and the only study in any
health profession to evaluate demonstration technique in
a blinded manner. Further, this is the first study to assess
differences in demonstration accuracy between original
EpiPen, new-look EpiPen and Anapen.
Main findings
Overall, 65% of pharmacists accurately demonstrated
the first three steps required for epinephrine injection.
However, only 18% of pharmacists performed all four steps
listed on the ASCIA Action Plan for Anaphylaxis [30] with
the proportion being twice as high for new-look EpiPen
and Anapen than for original EpiPen. Thus despite
more than 10 years of uninterrupted use of originalTable 5 Additional advice provided by pharmacists during co
Advice provided Original EpiPen
(n = 87)
Do you know what you reacted to? 66 (75.9)
Explain signs of anaphylaxisa 64 (73.6)
Call ambulance after using epinephrine 53 (60.9)
Identify expiry date of researcher’s device 53 (60.9)
Are you seeing an allergy specialist? 6 (6.9)
Conditions for device storage 20 (23)
Side effects of epinephrine 7 (8)
Do you have an anaphylaxis action plan? 4 (4.6)
*Pearson chi-squared p-value for comparison of advice provided across groups.
aPharmacist explained the signs of severe allergic reaction as listed on the relevant
bFisher’s exact test used.EpiPen in Australia, pharmacists performed worse
when demonstrating this device compared to the new
devices. Seemingly familiarity with a device does not
guarantee sound technique; rather being ‘unusual’ or
‘new’ may serve to make the user more careful.
In the broader context no other evaluation of device
technique has assessed the fourth step (remove device
after injection, do not touch needle, massage injection
site for 10 seconds). It is possible that pharmacists
considered this last step did not require explanation,
as it is obvious the device needs to be removed after
injection. Furthermore, the importance of massaging
the site is unknown, although it may provide comfort
from the puncture of the needle. Studies of epinephrine
autoinjector demonstration in physicians and patients focus
only on the three steps required for injection of original
EpiPen. These show that 21-41% of allergy specialists
[19,22]; 11-37% of other medical practitioners [19,21,31,32];
and 9-36% of patients and caregivers [25,26] accurately
performed those three steps. Therefore, against the 4-step
ASCIA standard [30] pharmacists had a low proportion
who demonstrated accurately, whereas in comparison with
previous research (3-step evaluation), pharmacists had the
highest proportions of accurate demonstrators.
Although all of the autoinjectors have the same cost
and are subsidised equally on the PBS, EpiPen is more
widely prescribed in Australia [15,33]. We expected
demonstration accuracy to be similar between the EpiPensnsultations (count and %)
New-look EpiPen Anapen Total P value*
(n = 92) (n = 87) (n = 266)
67 (72.8) 45 (51.7) 178 (66.9) 0.001
74 (80.4) 36 (41.4) 174 (65.4) <0.001
60 (65.2) 46 (52.9) 159 (59.8) 0.23
38 (41.3) 41 (47.1) 132 (49.6) 0.03
16 (17.4) 30 (34.5) 52 (19.5) <0.001
16 (17.4) 15 (17.2) 51 (19.2) 0.49
9 (9.8) 5 (5.7) 21 (7.9) 0.61
10 (10.9) 1 (1.1) 15 (5.6) 0.02b
ASCIA Action Plan for Anaphylaxis at the time of this research [30].
Table 6 Predictors of accurate self-injectable epinephrine demonstration by pharmacists* (n = 266)
Simple regression models Multiple regression model
Predictor OR 95% CI P value Adjusted OR 95% CI P value
Original EpiPen 0.64 0.35-1.19 0.16 0.21 0.07-0.63 0.006
New-look EpiPen 0.67 0.37-1.24 0.21 0.60 0.23-1.55 0.29
Anapena 1 1
Age 20-30 2.59 0.56-11.9 0.22 1.74 0.26-11.4 0.56
Age 31-40 1.87 0.39-8.95 0.43 1.59 0.24-10.4 0.63
Age 41-50 2.56 0.51-12.8 0.25 2.69 0.40-17.8 0.31
Age 51+a 1 1
Male 0.70 0.36-1.36 0.30 0.80 0.35-1.79 0.58
Reference materials consulted 0.96 0.51-1.81 0.89 0.75 0.34-1.67 0.48
Do you know what you reacted to? 1.98 0.93-4.12 0.08 1.49 0.53-4.12 0.45
Are you seeing an allergy specialist? 1.59 0.76-3.34 0.22 0.52 0.19-1.43 0.20
Explain signs of anaphylaxis 2.14 1.01-4.54 0.05 0.90 0.33-2.47 0.84
Do you have an anaphylaxis action plan? 17.0 5.12-56.3 <0.001 16.1 3.86-67.3 <0.001
Call ambulance after epinephrine 5.66 2.30-13.9 <0.001 4.00 1.44-11.1 0.008
Conditions for device storage 2.16 1.05-4.45 0.04 1.80 0.72-4.51 0.21
Explain side effects of epinephrine 5.28 2.09-13.3 <0.001 4.45 1.48-13.4 0.008
Identify expiry date of device 1.74 0.91-3.32 0.10 1.08 0.48-2.43 0.86
*Accurate device demonstration required all steps on the relevant ASCIA Action Plan for Anaphylaxis [30] to be performed without error.
OR = odds ratio; 95% CI = 95% confidence interval.
aReference level for the variable. Simple regression models assessed each predictor in a separate univariate model. The multiple regression model assessed all
predictors at once (model fit: Nagelkerke R2 = 0.33).
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ing that 4-step accuracy was significantly worse for original
EpiPen, and that there was no difference in 3-step accuracy
between all 3 devices. Given this research was conducted in
the midst of the change in device availability it is possible
pharmacists had been exposed to promotional materials
from the new autoinjector manufacturers, or had
undertaken self-directed learning to address a perceived
unfamiliarity with new-look EpiPen and Anapen.
Features of the consultation associated with accurate
demonstration
Our study found that three elements of the pharmacist’s
advice showed an association with accurate device
demonstration. Firstly, the odds of an accurate demonstra-
tion was 16 times higher if the pharmacist asked the
researcher ‘do you have an anaphylaxis action plan?’ In
Australia, patients prescribed epinephrine autoinjectors on
a PBS prescription must also receive an anaphylaxis
emergency management plan [33]. These plans are
prepared by the specialist allergist and rarely seen by
the patient’s pharmacist. Only 5.6% of pharmacists in
this study asked about an action plan, and in practice
less than half of all anaphylaxis patients actually have
an action plan [34,35]. Yet there is immense potential
for improvement in device demonstration, patient
preparedness and understanding of anaphylaxis withtheir use [3,8-11,36,37]. Judicious use of device-specific
anaphylaxis action plans in pharmacist consultations may
improve demonstration accuracy (especially since the
steps for demonstration are shown on the plan), while
reminding patients of the need to obtain their own plan.
Advising the researcher to call an ambulance after
epinephrine use was associated with a four-fold increase
in the odds of an accurate demonstration, and explaining
the side effects of epinephrine was associated with a 4.5
fold increase in the odds of an accurate demonstration.
Although 60% of pharmacists in this study recognised
the need for emergency care after epinephrine use,
[3,7-10,38-41] less than 10% of pharmacists explained
the side effects of epinephrine. Provision of medicines
and other information is fundamental to professional
pharmacist practice [42], and although there are benefits to
the patient in providing such advice (empowerment, com-
fort with intended use [43,44]), these elements cannot
alone predict technical expertise or accurate autoinjector
demonstration. Rather, they likely reflect a more detailed
understanding of anaphylaxis and epinephrine autoinjector
devices, and it is this deeper knowledge that contributes to
improved autoinjector demonstration accuracy.
Predictors of accurate epinephrine device demonstration
by physicians and patients relate to their experiences.
Regular allergy assessment, history of severe anaphylaxis
and recognition of the device are important predictors of
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onstration, prior consultation with a specialist and em-
powerment (including independently seeking information)
impact patient technique [21,24,43,45]. Given this was a
simulated patient study and pharmacists were unaware they
were being assessed, it was not possible to measure
experience as a predictor of accurate demonstration.
Relevance of demonstration errors
Common errors in demonstration were similar to those
observed in other studies [19,21,22,24,31,32,46]. Failure
to activate the device (5-21% of pharmacists), or to hold
it firmly in place for 10 seconds after injection (28%)
prevents or reduces the intramuscular dose of epinephrine
received. Positioning the thumb over either end of EpiPen
(11.8%) may result in unintentional injection to the thumb
and a lost dose for the patient. These errors are of
concern: in one-third of visits the researcher would
not have received epinephrine had they followed the
pharmacist’s instructions.
More than two-thirds of pharmacists in our study did
not inform the researcher of the fourth step: avoid the
exposed needle (original EpiPen and Anapen), and
massage the site after injection. These statements are
clearly defined in device-specific ASCIA Action Plans for
Anaphylaxis and in manufacturer information [30,47-49],
but are not printed in the instructions on either live or
trainer epinephrine autoinjector devices. There is no
information on the frequency or hazards of needle-stick
injury after intentional epinephrine autoinjector use. While
the clinical implication of failure to massage after injection
is unclear, a slower rate of epinephrine absorption or
injection site discomfort may be relevant. The lack of any
research amongst physicians, patients or carers involving
this step suggests it is not perceived to be important in
device administration. Similarly, it is likely that pharmacists
do not consider these ‘after-injection’ steps as relevant to
receiving a dose of epinephrine. As this research is the first
to evaluate the fourth step, future consideration of the need
for this step in inclusion in manufacturer information,
patient leaflets and anaphylaxis action plans is needed. As a
minimum, consistency across information sources (written
materials and autoinjector devices) should be a priority.
Strengths and limitations
In previous research on epinephrine autoinjector demon-
stration, users were 2.6 times more likely to perform
accurate demonstration when informed that the technique
would be assessed [50]. Therefore a key strength of this
study was the use of simulated patient methodology to
blind pharmacists to their assessment. This technique is
well described in the literature as a tool to measure
true pharmacist practice, and overcomes the issues of
participant bias that occurs when pharmacists knowthey will be evaluated [51,52]. Further, it is common in
Australia for patients to request advice over-the-counter
at a pharmacy without a product sale or prescription
purchase, so we did not consider the request would
arouse suspicion.
However, because we solicited the pharmacist’s advice
without a sale, we could not evaluate true patterns of
device demonstration that may occur when an epinephrine
autoinjector is actually dispensed. Moreover, the complex-
ities of PBS subsidies and high cost of self-injectable
epinephrine (currently more then AU$100 for one EpiPen
or Anapen) [33] preclude such an evaluation.
As we did not record the exchange between pharmacist
and simulated patient, we relied on researchers to
remember the consultation with the pharmacist and
acknowledge that recall bias was possible. Further we
note that the use of Master of Pharmacy students as
simulated patients presented the potential for bias in
scenario delivery or responses to pharmacist questions,
although we aimed to minimise this with predefined
statements for each researcher to use. In addition, as all
three simulated patients required sound knowledge of
anaphylaxis and epinephrine autoinjector technique (to be
able to judge and record the consultation), we cannot be
sure how a lay consumer would interpret and remember
the consultation. Nor did we evaluate whether the pharma-
cist asked the researcher to demonstrate the device back to
them, and in turn assess the true understanding gained as a
result of the pharmacist demonstration. This is an essential
part of device training and a gap in research that should be
addressed.
Finally, although we found three elements of pharmacist
advice were associated with significantly higher odds of
accurate demonstration (both independently and collect-
ively), they do not predict accurate demonstration within
themselves, but represent better knowledge of anaphylaxis
and autoinjector technique in general.
Implications and recommendations
This study showed pharmacists were willing to demonstrate
EpiPen and Anapen devices to patients even when they had
not supplied them and would not receive remuneration
for the service. Two-thirds of pharmacists under the
blinded real-world conditions of our study provided sound
demonstration advice, compared to one-third of physicians
in open evaluations [19,31,32]. Thus despite concerns
that pharmacists are poor demonstrators [53] we may
be reassured that most can show their patients how
to inject a dose of epinephrine. For the one-third of
pharmacists who failed to do so accurately, the use of
device-specific anaphylaxis action plans during demon-
stration may prompt improved accuracy.
While we recognise the importance of an holistic
approach in autoinjector device training, pharmacists
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ician review is not possible. Patients may wait months after
diagnosis for an appointment with their allergy specialist, or
only see their general practitioner when a new prescription
is required to replace an expired device (every 1–2 years)
[10]. Consultations may be time-restricted and patients may
be overwhelmed with new information, reducing the poten-
tial for a memorable device demonstration by physicians.
In-time retraining of autoinjector technique by pharmacists
should be considered to raise patients’ awareness and
competence with autoinjector devices.
Dealing with the errors in device technique is essential,
yet may be difficult to achieve because aspects critical
for epinephrine injection (such as pushing hard to inject,
holding the device in place for 10 seconds, or using the cor-
rect thumb position) are not intuitive. Novel approaches
should be developed for training. Beyond this training is
the need to prevent errors in the high-stress environment
of acute anaphylaxis. Performing device demonstrations
under pressure (such as with a timer), and then evaluating
patient technique similarly would be useful to prepare
patients to work quickly in real emergencies.Conclusions
Pharmacists in Australia dispense prescriptions for
epinephrine autoinjectors 70 times more often now
than ten years ago [15]. Given their important role,
and significant potential in anaphylaxis preparedness, it is
disappointing that only 18% of them accurately demon-
strated all four steps for autoinjector administration listed
on the ASCIA action plan for anaphylaxis [30]. However,
the fourth step is not relevant to the patient receiving a
dose of epinephrine and has not been not tested in any
other research. Moreover 65% of pharmacists accurately
demonstrated all 3 steps required for epinephrine injec-
tion from an autoinjector. Notably, this is the best demon-
stration accuracy observed in any health professional
group. Nonetheless there remains room for improvement.
Raising awareness of the need for action plans, emergency
care after epinephrine use, and informing patients about
the side effects of epinephrine may prompt recall of
epinephrine autoinjector technique and improve demon-
stration accuracy. This in turn may improve epinephrine
autoinjector use in the community and save lives.
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